Over One-Third of Under 50s Are Open to Psychedelic Trials for Mental Health Treatment
Aside from psilocybin, those aged between 18-24 were most interested psychedelic trials with ketamine (27%) and MDMA (26%).
Day: August 29, 2023
End of content
End of content